Back to top
more

Regeneron Pharmaceuticals (REGN)

(Delayed Data from NSDQ)

$558.87 USD

558.87
1,656,434

+13.41 (2.46%)

Updated Aug 1, 2025 04:00 PM ET

After-Market: $559.71 +0.84 (0.15%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Amgen's Repatha Wins Over Sanofi & Regeneron's Praluent

by Zacks Equity Research

The U.S. District Court in Delaware granted Amgen, Inc. (AMGN) permanent injunction against infringement by Sanofi and Regeneron of two patents owned by the former for Repatha.

    Zacks Equity Research

    4 Biotech Stocks with Bright Prospects in 2017

    by Zacks Equity Research

    Even as the drug pricing issue continues to plague the biotech sector, investors should find it safe to bet on these top-ranked biotech stocks that also have superb Style Score as markets roll into 2017.

      Arpita Dutt headshot

      Regeneron vs. Vertex: Which Stock is a Better Pick?

      by Arpita Dutt

      Both Regeneron (REGN) and Vertex look set for a rebound in 2017 after a tough and challenging 2016.

        Zacks Equity Research

        Stock Market News for December 27, 2016

        by Zacks Equity Research

        Major U.S. benchmarks ended the last trading session ahead of Christmas holiday on a positive note as investors continued to cheer Trump's promises.

          Arpita Dutt headshot

          Forget Alexion (ALXN), Buy These 3 Biotech Stocks Instead

          by Arpita Dutt

          We advise investors to focus on biotech stocks which sport a strong Zacks Rank and have interesting pipelines/products and growth potential.

            Zacks Equity Research

            7 Stocks to Buy with Impressive Interest Coverage Ratio

            by Zacks Equity Research

            Interest Coverage Ratio is used to determine how effectively a company can pay the interest charged on its debt.

              Zacks Equity Research

              4 Growth Stocks to Buy Amid Obamacare Repeal Talks

              by Zacks Equity Research

              Affordable Care Act (ACA) has been one of the most discussed topics during the 2016 U.S. presidential election. Even after a month, it has been contributing to the discord in the healthcare investment market.

                Zacks Equity Research

                The Zacks Analyst Blog Highlights: Celgene, Regeneron Pharmaceuticals, Ophthotech and Exelixis

                by Zacks Equity Research

                The Zacks Analyst Blog Highlights: Celgene, Regeneron Pharmaceuticals, Ophthotech and Exelixis

                  Arpita Dutt headshot

                  Biotech Stock Roundup: Ophthotech Slumps on Fovista Results, Achaogen Skyrockets on Data

                  by Arpita Dutt

                  Several companies presented data this week with companies like Achaogen (AKAO) soaring while others like Ophthotech plunged.

                    Zacks Equity Research

                    Ophthotech Hits 52-Week Low on Unfavorable Fovista Data

                    by Zacks Equity Research

                    Ophthotech's (OPHT) shares tumbled 86.4% to a 52-week low after the company reported disappointing phase III data on its eye drug, Fovista, in wet AMD patients.

                      Arpita Dutt headshot

                      3 Great Stocks to Beat the Biotech Blues

                      by Arpita Dutt

                      Are you on the lookout for some good biotech stocks this month? Here are three that warrant a look.

                        Arpita Dutt headshot

                        Should Biotech Investors Worry About Donald Trump?

                        by Arpita Dutt

                        It looks like biotech investors may have heaved a sigh of relief a bit too early when Presidential election results were announced last month.

                          Zacks Equity Research

                          The Zacks Analyst Blog Highlights: Booz Allen Hamilton Holding, McDonald's, Regions Financial and Regeneron Pharmaceuticals

                          by Zacks Equity Research

                          The Zacks Analyst Blog Highlights: Booz Allen Hamilton Holding, McDonald's, Regions Financial and Regeneron Pharmaceuticals

                            Arpita Dutt headshot

                            Play the Trump Factor with these 4 Large-Cap Stocks

                            by Arpita Dutt

                            Diversify your portfolio by investing in blue-chip stocks with a proven track record and a certain level of financial strength, resilience & stability.

                              Zacks Equity Research

                              5 Top Performing Biotechnology Stocks of November

                              by Zacks Equity Research

                              November was a great month for pharma/biotech stocks after a rather difficult year when the industry struggled with media and political focus on high drug prices.

                                Zacks Equity Research

                                Buy 7 Stocks with Impressive Interest Coverage Ratio

                                by Zacks Equity Research

                                Interest Coverage Ratio is used to determine how effectively a company can pay the interest charges on its debt.

                                  Zacks Equity Research

                                  NVIDIA, Sotheby's Holdings, Celgene, Regeneron Pharmaceuticals and Sanofi highlighted as Zacks Bull and Bear of the Day

                                  by Zacks Equity Research

                                  NVIDIA, Sotheby's Holdings, Celgene, Regeneron Pharmaceuticals and Sanofi highlighted as Zacks Bull and Bear of the Day

                                    Arpita Dutt headshot

                                    Celgene vs. Regeneron: Which Stock is a Better Pick?

                                    by Arpita Dutt

                                    Both Celgene (CELG) and Regeneron (REGN) are Zacks Rank #2 (Buy) stocks; which one of these two stocks is a better choice for investors?

                                      Zacks Equity Research

                                      The Zacks Analyst Blog Highlights: Allergan, Gilead Sciences, Pfizer, Regeneron Pharmaceuticals and Lion Biotechnologies

                                      by Zacks Equity Research

                                      The Zacks Analyst Blog Highlights: Allergan, Gilead Sciences, Pfizer, Regeneron Pharmaceuticals and Lion Biotechnologies